FDA Approves Afatinib for Advanced Lung Cancer

The FDA approved afatinib (Gilotrif) as a first-line therapy for patients with metastatic non-small-cell lung cancer whose tumors harbor certain mutations in the epidermal growth factor receptor gene.
Source: Cancer Network - Category: Cancer & Oncology Source Type: news